Carolina Schinke
Concepts (315)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 73 | 2024 | 2929 | 8.480 |
Why?
| Hematopoietic Stem Cell Transplantation | 9 | 2024 | 565 | 2.230 |
Why?
| Antibodies, Bispecific | 6 | 2024 | 60 | 1.920 |
Why?
| B-Cell Maturation Antigen | 8 | 2024 | 90 | 1.750 |
Why?
| Bone Marrow | 11 | 2024 | 362 | 1.410 |
Why?
| Leukemia, Plasma Cell | 2 | 2020 | 33 | 1.390 |
Why?
| Neoplasms, Plasma Cell | 3 | 2024 | 37 | 1.340 |
Why?
| Paraproteinemias | 2 | 2022 | 72 | 1.330 |
Why?
| Immunotherapy, Adoptive | 6 | 2024 | 156 | 1.230 |
Why?
| Humans | 88 | 2024 | 49974 | 1.200 |
Why?
| Neoplasm, Residual | 6 | 2022 | 165 | 1.180 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 103 | 1.140 |
Why?
| Immunoglobulin Light Chains | 2 | 2017 | 81 | 1.060 |
Why?
| Transplantation, Autologous | 10 | 2024 | 466 | 1.040 |
Why?
| Myelodysplastic Syndromes | 5 | 2016 | 81 | 0.930 |
Why?
| Immunoconjugates | 2 | 2022 | 38 | 0.910 |
Why?
| Mutation | 8 | 2022 | 1294 | 0.910 |
Why?
| Antibodies, Monoclonal | 6 | 2023 | 459 | 0.830 |
Why?
| Leukemia, Myeloid, Acute | 4 | 2019 | 185 | 0.820 |
Why?
| Health Personnel | 1 | 2024 | 246 | 0.780 |
Why?
| Gene Expression Regulation, Neoplastic | 9 | 2024 | 828 | 0.780 |
Why?
| Gene Expression Profiling | 10 | 2023 | 1032 | 0.760 |
Why?
| Prognosis | 15 | 2024 | 1942 | 0.750 |
Why?
| Testis | 1 | 2021 | 69 | 0.730 |
Why?
| Aged | 23 | 2024 | 9310 | 0.730 |
Why?
| Hematopoietic Stem Cells | 3 | 2019 | 184 | 0.690 |
Why?
| Cell Proliferation | 8 | 2023 | 1007 | 0.660 |
Why?
| Clonal Evolution | 4 | 2024 | 56 | 0.660 |
Why?
| Gene Expression | 3 | 2018 | 609 | 0.640 |
Why?
| Middle Aged | 22 | 2024 | 12069 | 0.590 |
Why?
| Clinical Trials as Topic | 6 | 2023 | 461 | 0.590 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 989 | 0.580 |
Why?
| Male | 29 | 2024 | 25241 | 0.580 |
Why?
| Signal Transduction | 5 | 2024 | 1618 | 0.580 |
Why?
| Translocation, Genetic | 5 | 2021 | 264 | 0.570 |
Why?
| Thoracic Neoplasms | 1 | 2016 | 13 | 0.540 |
Why?
| Plasmacytoma | 1 | 2016 | 42 | 0.520 |
Why?
| Receptors, Interleukin-8B | 1 | 2015 | 4 | 0.510 |
Why?
| Tumor Microenvironment | 4 | 2024 | 212 | 0.500 |
Why?
| Interleukin-8 | 1 | 2015 | 87 | 0.490 |
Why?
| Adult | 18 | 2024 | 13236 | 0.480 |
Why?
| Plasma Cells | 5 | 2023 | 223 | 0.460 |
Why?
| Receptors, G-Protein-Coupled | 2 | 2024 | 53 | 0.450 |
Why?
| Survival Analysis | 7 | 2021 | 653 | 0.450 |
Why?
| Antineoplastic Agents | 7 | 2024 | 1171 | 0.440 |
Why?
| Female | 25 | 2024 | 26472 | 0.430 |
Why?
| Combined Modality Therapy | 4 | 2024 | 637 | 0.420 |
Why?
| Stem Cell Transplantation | 4 | 2024 | 181 | 0.420 |
Why?
| Fluorodeoxyglucose F18 | 5 | 2021 | 192 | 0.410 |
Why?
| Neutropenia | 2 | 2023 | 116 | 0.410 |
Why?
| DNA Methylation | 4 | 2020 | 548 | 0.400 |
Why?
| Oncogene Proteins, Fusion | 2 | 2018 | 58 | 0.390 |
Why?
| Neoplasms, Second Primary | 2 | 2024 | 78 | 0.390 |
Why?
| Chromosomes, Human, Pair 1 | 3 | 2023 | 93 | 0.380 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 47 | 0.380 |
Why?
| Neoplasm Recurrence, Local | 7 | 2024 | 614 | 0.380 |
Why?
| Positron-Emission Tomography | 4 | 2022 | 295 | 0.370 |
Why?
| Epigenesis, Genetic | 4 | 2020 | 374 | 0.370 |
Why?
| Evolution, Molecular | 2 | 2021 | 99 | 0.360 |
Why?
| Tretinoin | 1 | 2010 | 53 | 0.350 |
Why?
| Treatment Outcome | 10 | 2024 | 5141 | 0.340 |
Why?
| Risk Assessment | 4 | 2024 | 1259 | 0.330 |
Why?
| Immunoglobulin kappa-Chains | 2 | 2021 | 22 | 0.330 |
Why?
| Transcription Factors | 3 | 2023 | 561 | 0.320 |
Why?
| Aged, 80 and over | 7 | 2021 | 3129 | 0.310 |
Why?
| DNA-Binding Proteins | 2 | 2021 | 427 | 0.300 |
Why?
| Neoplasm Proteins | 3 | 2020 | 322 | 0.300 |
Why?
| Cell Line, Tumor | 6 | 2024 | 1403 | 0.290 |
Why?
| Melanoma | 1 | 2010 | 285 | 0.280 |
Why?
| Transcriptome | 2 | 2020 | 315 | 0.280 |
Why?
| Disease Progression | 7 | 2023 | 825 | 0.270 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 92 | 0.260 |
Why?
| Biopsy | 2 | 2018 | 584 | 0.260 |
Why?
| Radiopharmaceuticals | 3 | 2021 | 209 | 0.250 |
Why?
| Skin Neoplasms | 1 | 2010 | 488 | 0.250 |
Why?
| Dexamethasone | 3 | 2024 | 430 | 0.240 |
Why?
| Chemokine CXCL12 | 1 | 2024 | 32 | 0.240 |
Why?
| T-Lymphocytes | 5 | 2024 | 338 | 0.240 |
Why?
| Kaplan-Meier Estimate | 3 | 2021 | 466 | 0.240 |
Why?
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2024 | 2 | 0.240 |
Why?
| Pentaerythritol Tetranitrate | 1 | 2024 | 6 | 0.240 |
Why?
| Antigens, CD19 | 1 | 2024 | 24 | 0.230 |
Why?
| Mutation Rate | 2 | 2021 | 36 | 0.230 |
Why?
| Genome-Wide Association Study | 1 | 2024 | 166 | 0.230 |
Why?
| Myeloproliferative Disorders | 1 | 2023 | 27 | 0.220 |
Why?
| Cell Cycle | 2 | 2021 | 231 | 0.220 |
Why?
| Neoplasm Staging | 2 | 2024 | 740 | 0.220 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 79 | 0.210 |
Why?
| Drug Resistance, Neoplasm | 1 | 2024 | 308 | 0.210 |
Why?
| Qualitative Research | 1 | 2024 | 329 | 0.210 |
Why?
| Genomics | 2 | 2023 | 286 | 0.200 |
Why?
| Osteolysis | 1 | 2022 | 75 | 0.200 |
Why?
| Drug Approval | 1 | 2022 | 47 | 0.200 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2022 | 40 | 0.200 |
Why?
| Lymphoma, B-Cell | 1 | 2022 | 63 | 0.200 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2024 | 485 | 0.200 |
Why?
| Hematologic Diseases | 1 | 2021 | 22 | 0.200 |
Why?
| Bone Marrow Transplantation | 1 | 2022 | 116 | 0.200 |
Why?
| Epigenomics | 1 | 2021 | 67 | 0.200 |
Why?
| Patient Participation | 1 | 2022 | 66 | 0.190 |
Why?
| Genetic Predisposition to Disease | 1 | 2024 | 510 | 0.190 |
Why?
| Abnormal Karyotype | 1 | 2021 | 6 | 0.190 |
Why?
| Chromosome Deletion | 2 | 2023 | 140 | 0.190 |
Why?
| Myeloma Proteins | 1 | 2021 | 24 | 0.190 |
Why?
| Immunoglobulin A | 1 | 2021 | 45 | 0.190 |
Why?
| Drug Design | 2 | 2013 | 120 | 0.190 |
Why?
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 123 | 0.190 |
Why?
| Communicable Diseases | 1 | 2021 | 55 | 0.190 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 225 | 0.190 |
Why?
| Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.180 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2020 | 33 | 0.180 |
Why?
| Hematologic Neoplasms | 1 | 2022 | 99 | 0.180 |
Why?
| Practice Guidelines as Topic | 1 | 2023 | 449 | 0.180 |
Why?
| Salvage Therapy | 1 | 2021 | 139 | 0.180 |
Why?
| Immunoglobulin G | 1 | 2021 | 186 | 0.180 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.180 |
Why?
| Neoplasm Invasiveness | 1 | 2021 | 267 | 0.180 |
Why?
| Bone Resorption | 1 | 2022 | 304 | 0.170 |
Why?
| Bone Diseases | 1 | 2021 | 99 | 0.170 |
Why?
| Gene Amplification | 1 | 2019 | 57 | 0.170 |
Why?
| Atrial Fibrillation | 1 | 2022 | 180 | 0.170 |
Why?
| Chromosomal Instability | 1 | 2019 | 16 | 0.170 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 107 | 0.170 |
Why?
| Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.170 |
Why?
| Healthcare Disparities | 1 | 2022 | 257 | 0.170 |
Why?
| United States | 3 | 2024 | 4860 | 0.160 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.160 |
Why?
| Comorbidity | 1 | 2021 | 615 | 0.160 |
Why?
| Sulfonamides | 1 | 2019 | 129 | 0.160 |
Why?
| Mice | 5 | 2024 | 5739 | 0.160 |
Why?
| Models, Statistical | 1 | 2020 | 224 | 0.160 |
Why?
| Spleen | 1 | 2019 | 172 | 0.160 |
Why?
| Risk Factors | 7 | 2021 | 3613 | 0.160 |
Why?
| Phosphotransferases | 1 | 2018 | 16 | 0.160 |
Why?
| Spinal Fractures | 1 | 2018 | 38 | 0.160 |
Why?
| Bacteremia | 1 | 2019 | 90 | 0.150 |
Why?
| Adipocytes | 1 | 2018 | 121 | 0.150 |
Why?
| Cell Differentiation | 3 | 2022 | 651 | 0.150 |
Why?
| Gene Rearrangement | 1 | 2018 | 74 | 0.150 |
Why?
| Kidney Function Tests | 1 | 2017 | 49 | 0.150 |
Why?
| Disease-Free Survival | 4 | 2019 | 454 | 0.150 |
Why?
| Hexokinase | 1 | 2017 | 17 | 0.150 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2017 | 36 | 0.140 |
Why?
| Glomerular Filtration Rate | 1 | 2017 | 111 | 0.140 |
Why?
| Calcification, Physiologic | 1 | 2017 | 41 | 0.140 |
Why?
| Survival Rate | 4 | 2020 | 894 | 0.140 |
Why?
| HIV Infections | 1 | 2021 | 357 | 0.140 |
Why?
| Pelvis | 1 | 2017 | 68 | 0.140 |
Why?
| Histoplasma | 1 | 2016 | 27 | 0.140 |
Why?
| Chromosome Aberrations | 2 | 2023 | 297 | 0.140 |
Why?
| CA-125 Antigen | 1 | 2016 | 17 | 0.140 |
Why?
| Receptor, TIE-2 | 1 | 2016 | 16 | 0.140 |
Why?
| Cardiomyopathy, Restrictive | 1 | 2016 | 5 | 0.140 |
Why?
| Animals | 7 | 2024 | 13187 | 0.140 |
Why?
| Urea | 1 | 2016 | 77 | 0.140 |
Why?
| Histoplasmosis | 1 | 2016 | 50 | 0.140 |
Why?
| Indazoles | 1 | 2016 | 47 | 0.130 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 96 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 181 | 0.130 |
Why?
| Remission Induction | 3 | 2024 | 207 | 0.130 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2017 | 202 | 0.130 |
Why?
| Gastrointestinal Diseases | 1 | 2016 | 126 | 0.130 |
Why?
| Proteasome Inhibitors | 1 | 2016 | 104 | 0.130 |
Why?
| Immunologic Factors | 1 | 2016 | 114 | 0.120 |
Why?
| Cell Cycle Checkpoints | 1 | 2015 | 32 | 0.120 |
Why?
| Kidney Diseases | 1 | 2017 | 214 | 0.120 |
Why?
| Time Factors | 2 | 2021 | 2903 | 0.120 |
Why?
| Cluster Analysis | 1 | 2015 | 235 | 0.120 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2015 | 211 | 0.120 |
Why?
| Recurrence | 4 | 2021 | 652 | 0.120 |
Why?
| Thrombopoiesis | 1 | 2014 | 5 | 0.120 |
Why?
| Myocardium | 1 | 2017 | 436 | 0.120 |
Why?
| Hydrazines | 1 | 2014 | 15 | 0.120 |
Why?
| Benzoates | 1 | 2014 | 22 | 0.120 |
Why?
| Neoplastic Stem Cells | 1 | 2015 | 103 | 0.120 |
Why?
| Immunotherapy | 1 | 2016 | 238 | 0.110 |
Why?
| Demography | 2 | 2024 | 93 | 0.110 |
Why?
| Cystatin M | 2 | 2024 | 20 | 0.110 |
Why?
| Retrospective Studies | 5 | 2024 | 6108 | 0.110 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 1557 | 0.110 |
Why?
| Disease Models, Animal | 2 | 2016 | 1455 | 0.110 |
Why?
| Pyrazoles | 1 | 2014 | 113 | 0.110 |
Why?
| Cell Survival | 1 | 2015 | 600 | 0.110 |
Why?
| Chromosomes, Human, Pair 7 | 1 | 2012 | 29 | 0.100 |
Why?
| Clone Cells | 2 | 2023 | 74 | 0.100 |
Why?
| Cardiovascular Diseases | 1 | 2017 | 440 | 0.100 |
Why?
| STAT3 Transcription Factor | 1 | 2012 | 81 | 0.100 |
Why?
| Chromatin | 2 | 2024 | 151 | 0.100 |
Why?
| Cell Transformation, Neoplastic | 1 | 2013 | 177 | 0.100 |
Why?
| Follow-Up Studies | 3 | 2024 | 2182 | 0.100 |
Why?
| Thalidomide | 1 | 2014 | 377 | 0.100 |
Why?
| Flow Cytometry | 2 | 2012 | 476 | 0.100 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2023 | 259 | 0.090 |
Why?
| Leukemia, Promyelocytic, Acute | 1 | 2010 | 11 | 0.090 |
Why?
| Luciferases | 1 | 2010 | 50 | 0.090 |
Why?
| Response Elements | 1 | 2010 | 29 | 0.090 |
Why?
| Gene Silencing | 1 | 2010 | 119 | 0.090 |
Why?
| Alleles | 2 | 2021 | 250 | 0.090 |
Why?
| Tumor Burden | 2 | 2020 | 132 | 0.090 |
Why?
| Transfection | 1 | 2010 | 354 | 0.080 |
Why?
| Recombinant Fusion Proteins | 1 | 2010 | 181 | 0.080 |
Why?
| Molecular Structure | 1 | 2010 | 297 | 0.080 |
Why?
| Histones | 2 | 2021 | 312 | 0.080 |
Why?
| Apoptosis | 2 | 2014 | 1101 | 0.080 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 110 | 0.080 |
Why?
| Syndecan-1 | 2 | 2021 | 72 | 0.080 |
Why?
| Case-Control Studies | 2 | 2024 | 1131 | 0.070 |
Why?
| Tumor Cells, Cultured | 2 | 2020 | 465 | 0.070 |
Why?
| Imaging, Three-Dimensional | 2 | 2017 | 151 | 0.070 |
Why?
| Gene Expression Regulation | 1 | 2010 | 976 | 0.060 |
Why?
| Transmembrane Activator and CAML Interactor Protein | 1 | 2024 | 6 | 0.060 |
Why?
| Mendelian Randomization Analysis | 1 | 2024 | 7 | 0.060 |
Why?
| Telomere | 1 | 2024 | 36 | 0.060 |
Why?
| Arkansas | 2 | 2021 | 1977 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2024 | 33 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 18 | 0.060 |
Why?
| X-Ray Microtomography | 1 | 2024 | 77 | 0.060 |
Why?
| Antibodies | 1 | 2024 | 154 | 0.060 |
Why?
| B-Lymphocytes | 1 | 2024 | 170 | 0.060 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2023 | 51 | 0.060 |
Why?
| Cell Communication | 1 | 2023 | 69 | 0.050 |
Why?
| Neoplasms | 1 | 2013 | 1235 | 0.050 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| Patients | 1 | 2022 | 49 | 0.050 |
Why?
| Geography | 1 | 2022 | 61 | 0.050 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2022 | 33 | 0.050 |
Why?
| Patient Selection | 1 | 2023 | 253 | 0.050 |
Why?
| United States Food and Drug Administration | 1 | 2022 | 93 | 0.050 |
Why?
| Infant | 1 | 2010 | 3567 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 57 | 0.050 |
Why?
| Phylogeny | 1 | 2022 | 235 | 0.050 |
Why?
| Tomography, X-Ray Computed | 2 | 2017 | 1159 | 0.050 |
Why?
| RANK Ligand | 1 | 2022 | 179 | 0.050 |
Why?
| SOXC Transcription Factors | 1 | 2021 | 13 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2021 | 121 | 0.050 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 105 | 0.050 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 66 | 0.050 |
Why?
| Cyclin D2 | 1 | 2020 | 20 | 0.050 |
Why?
| Aneuploidy | 1 | 2020 | 16 | 0.050 |
Why?
| Pyrimidines | 1 | 2022 | 192 | 0.050 |
Why?
| Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.050 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2020 | 31 | 0.050 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2020 | 54 | 0.050 |
Why?
| Histone Code | 1 | 2020 | 32 | 0.050 |
Why?
| Cyclin D1 | 1 | 2020 | 56 | 0.050 |
Why?
| ras Proteins | 1 | 2020 | 64 | 0.050 |
Why?
| Genome, Human | 1 | 2021 | 111 | 0.050 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2020 | 75 | 0.050 |
Why?
| Protein Kinase Inhibitors | 1 | 2022 | 204 | 0.040 |
Why?
| DNA, Neoplasm | 1 | 2020 | 147 | 0.040 |
Why?
| Health Status Disparities | 1 | 2022 | 195 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2020 | 175 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 213 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 169 | 0.040 |
Why?
| Osteoclasts | 1 | 2022 | 425 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 577 | 0.040 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2019 | 26 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 214 | 0.040 |
Why?
| Pseudomonas Infections | 1 | 2019 | 48 | 0.040 |
Why?
| Syndrome | 1 | 2019 | 237 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2021 | 549 | 0.040 |
Why?
| Fractures, Compression | 1 | 2018 | 17 | 0.040 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 51 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 475 | 0.040 |
Why?
| Protein-Tyrosine Kinases | 1 | 2018 | 95 | 0.040 |
Why?
| False Positive Reactions | 1 | 2017 | 63 | 0.040 |
Why?
| Bone and Bones | 1 | 2021 | 469 | 0.040 |
Why?
| Itraconazole | 1 | 2016 | 40 | 0.040 |
Why?
| Databases, Factual | 1 | 2020 | 658 | 0.040 |
Why?
| Amino Acid Sequence | 1 | 2018 | 585 | 0.040 |
Why?
| beta-Glucans | 1 | 2016 | 23 | 0.040 |
Why?
| Alkaline Phosphatase | 1 | 2017 | 94 | 0.040 |
Why?
| Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| Angiopoietin-1 | 1 | 2016 | 16 | 0.030 |
Why?
| Amphotericin B | 1 | 2016 | 110 | 0.030 |
Why?
| Genes, p53 | 1 | 2016 | 51 | 0.030 |
Why?
| Ileum | 1 | 2016 | 89 | 0.030 |
Why?
| Intestinal Obstruction | 1 | 2016 | 36 | 0.030 |
Why?
| NF-kappa B | 1 | 2018 | 314 | 0.030 |
Why?
| Colonoscopy | 1 | 2016 | 93 | 0.030 |
Why?
| Glycolysis | 1 | 2016 | 70 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2016 | 106 | 0.030 |
Why?
| Models, Genetic | 1 | 2016 | 170 | 0.030 |
Why?
| Genomic Instability | 1 | 2016 | 92 | 0.030 |
Why?
| Staphylococcal Infections | 1 | 2019 | 268 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2016 | 136 | 0.030 |
Why?
| Fever | 1 | 2016 | 114 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 106 | 0.030 |
Why?
| Logistic Models | 1 | 2018 | 888 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 141 | 0.030 |
Why?
| Heart | 1 | 2017 | 326 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2016 | 402 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 615 | 0.030 |
Why?
| Echocardiography | 1 | 2017 | 378 | 0.030 |
Why?
| Weight Loss | 1 | 2016 | 237 | 0.030 |
Why?
| Megakaryocyte Progenitor Cells | 1 | 2014 | 1 | 0.030 |
Why?
| Young Adult | 1 | 2024 | 3958 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2016 | 688 | 0.030 |
Why?
| Antifungal Agents | 1 | 2016 | 339 | 0.030 |
Why?
| Models, Immunological | 1 | 2013 | 8 | 0.030 |
Why?
| Chemistry, Pharmaceutical | 1 | 2013 | 32 | 0.030 |
Why?
| Early Diagnosis | 1 | 2013 | 88 | 0.030 |
Why?
| Azacitidine | 1 | 2012 | 34 | 0.030 |
Why?
| Karyotyping | 1 | 2012 | 83 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2012 | 61 | 0.030 |
Why?
| Cell Lineage | 1 | 2012 | 83 | 0.030 |
Why?
| Polymerase Chain Reaction | 1 | 2013 | 453 | 0.020 |
Why?
| Child | 1 | 2024 | 6847 | 0.020 |
Why?
| Antigens, CD | 1 | 2012 | 219 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2013 | 391 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2017 | 1537 | 0.020 |
Why?
| Cytokines | 1 | 2013 | 612 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2013 | 1193 | 0.020 |
Why?
| Cohort Studies | 1 | 2013 | 1422 | 0.020 |
Why?
|
|
Schinke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|